U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07947823) titled 'ASTAR: Sacituzumab Govitecan For Breast Cancer' on Nov. 13.
Brief Summary: The goal of this clinical trial is to assess the safety and tolerability of sacituzumab govitecan followed by docetaxel and cyclophosphamide for individuals with high-risk early-stage HR+/HER2- breast cancer. The main questions it aims to answer are:
* Is sacituzumab govitecan safe for individuals with this type of cancer?
* Is sacituzumab govitecan effective in curing this type of cancer? Participants will receive up to 8 cycles of sacituzumab govitecan with chemotherapy.
Study Start Date: April 21, 2027
Study Type: INTERVENTIONAL
Condition:
Breast Can...